RG
CTMX icon

Redmile Group’s CytomX Therapeutics CTMX Stock Holding History

Redmile Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-262,400
Closed -$6M – 87
2018
Q2 		$6M Sell
262,400
-72,280
-22% -$1.85M 0.2% 59
2018
Q1 		$9.52M Sell
334,680
-84,000
-20% -$2.4M 0.37% 51
2017
Q4 		$8.84M Buy
418,680
+36,409
+10% +$755K 0.38% 52
2017
Q3 		$6.95M Sell
382,271
-316,121
-45% -$4.93M 0.34% 50
2017
Q2 		$10.8M Buy
698,392
+16,500
+2% +$249K 0.66% 45
2017
Q1 		$11.8M Sell
681,892
-15,100
-2% -$199K 0.76% 44
2016
Q4 		$7.66M Sell
696,992
-17,700
-2% -$214K 0.66% 34
2016
Q3 		$11.2M Sell
714,692
-19,207
-3% -$232K 0.89% 30
2016
Q2 		$7.5M Buy
733,899
+4,200
+0.6% +$47.9K 0.72% 34
2016
Q1 		$9.41M Sell
729,699
-8,657
-1% -$120K 0.96% 27
2015
Q4 		$14.4M Buy
+738,356
New +$11.7M 1.08% 28

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Redmile Group's CTMX Position: Q3 2018 in Review

Redmile Group sold out of CytomX Therapeutics (CTMX) in Q3 2018, closing a stake of 262,400 shares — an estimated $6M sold.

Redmile Group first reported a position in CTMX in Q4 2015 and held it in 11 quarters. The position peaked at $14.4M in Q4 2015. 122 funds tracked by Wall St. Rank hold CTMX as of Q3 2018.

  • Redmile Group reported no remaining CytomX Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Redmile Group sold 262,400 CytomX Therapeutics shares in Q3 2018, an estimated $6M.
  • Redmile Group first reported a position in CytomX Therapeutics in Q4 2015 and held it in 11 quarters.
  • Redmile Group's CytomX Therapeutics position peaked at $14.4M in Q4 2015.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2018.

Based on Redmile Group's 13F filing for Q3 2018, filed 14 Nov 2018.